Get started

Stockmarketsignals

Nifty Levels & Strategy for 09/Dec/2022Dear traders, I have identified chart levels based on my analysis, major support & resistance levels. Please note that I am not a SEBI registered member. Information shared by me here for educational purpose only. Please don’t trust me or anyone for trading/investment purpose as it may lead to financial losses. Focus on learning, how to fish, trust on your own trading skills and please do consult your financial advisor before trading. Nifty: Today Nifty defended the support levels & again started heading towards 19K level. FIIs were super bearish from last 2 days. Today, they switched the gear and became bullish in F&O after Gujarat election results. They are still net seller in cash segment in Dec. Two major events are over now RBI policy (specially commentary) & election results. Now, market will wait for US Fed policy in next week. Buying momentum is strong. Option data is indicating mild bullish move. Retail traders should look for buy on dips opportunity, book profit near lifetime highs & simply follow the trend till Nifty continue to respect & hold the major support levels. Please find below scorecard, PCR update & options statistics for your reference: NIFTY SCORECARD DATED 08/DEC/2022 NIFTY IS UP BY 49 POINTS Name Price Previous Day Change % Change Nifty 18609 18561 48.85 0.26% India VIX 13.40 14.08 -0.68 -4.83% OPTION STATISTICS BASED ON 15/DEC/2022 EXPIRY DATA Max OI (Calls) 18600 (Open Interest: 6106300, CE LTP: 138) Max OI (Puts) 18600 (Open Interest: 5680700, PE LTP: 83) PCR 0.75 (PCR is in bearish zone) Nifty Calls: ATM: Short Buildup, OTM:Short Buildup, ITM:Long Buildup, FAR OTM:Short Buildup Nifty Puts: ATM: Short Buildup, OTM:Short Buildup, ITM:Short Buildup, FAR OTM:Short Buildup
NSE:NIFTY
by manishmgupta
1
Nifty Levels & Strategy for 08/09/2022Dear traders, I have identified chart levels based on my analysis, major support, and resistance levels. Please note that I am not a SEBI registered member. Information shared here for educational purpose. Please don’t trust me or anyone for trading/investment purpose. Focus on learning how to fish, trust your own skills and please do consult your financial advisor before trading. NIFTY Nifty is down by just -31.2 points. PCR shifted slightly up from 0.87 ( bearish zone) to 0.92 ( bearish zone). Nifty hit the target as expected then reversed as well. Later option writer made good money as Nifty traded in a narrow range. Call writers are getting challenged again & again. Today morning put writers run for the cover & majority of them ended up booking losses. Smart traders made money who took contra trades at major support. Highest open interest on call side at 17800 (Shifted up from 17800 to 18000) Highest open interest on put side at 17000 (Remained at same level) BANK NIFTY Bank Nifty is down by -210.6 points. Bank Nifty offered excellent opportunities to option writers (short straddle/strangle traders). PCR shifted down from 0.91 ( bearish zone) to 0.78 (getting close to oversold zone). Bank Nifty closed above VWAP and important support zone with good buying volume which is indicating positive move is likely in Bank Nifty . Let us see how global cues works out tonight. Highest open interest on call side at 40000 (Remained at same level) Highest open interest on put side at 39000 (Remained at same level) Shall we continue look for sell on rise opportunities near major resistance levels with strict SL? and Shall we continue look for buy on dips opportunities near major support levels till indices are trading in a range? Please do share your comments. Have a very happy, healthy & profitable day ahead!
NSE:NIFTYLong
by manishmgupta
TideWaterOil - Positive BreakoutTidewaterOil declined from high of 3873 on 13/07/2021 down to 1397 on 20/12/2021, since when it is undergoing healthy consolidation. Three positive divergences occured during the period of 26/11/2021 to 18/01/2022. Also, fundamentally, results have not declined at all to the comparable level of downfall in the prices. Hence, it is a good price formation for upward journey from here on. Disc.: Consult your financial advisor or apply your self study to take any investment decision on this counter.
NSE:VEEDOLLong
by TechnoFunda_Investor
ES1! / S&P500 / LONG / The Market Has Taken it's BreadthThe market has taken it's breadth, and we move ONWARD! Multiple Bullish signals present for the upcoming trading week. -Daily Candle closed above the 50day MA -Classic inverted H&S Pattern -Profit Target 1: set at 4528.75, this level holds confluence with resistance + prior trend line. -Profit Target 2: set at 4596.50, this is the price target of the inverted H&S pattern. This trade will probably play out in 2 separate trades, I have entered at $4460, stop loss set at 4450. I will hold these contracts until PROFIT TARGET 1 is met, selling at that level and watching it closely to see if it can break resistance. IF resistance is broken, I will enter again and aim for PROFIT TARGET 2, selling there. Profit Target 2 may be adjusted based off the price action I see after resistance is broken, but for the time being that's where it's set. WHEN THE MARKET IS GIVING CLEAR SIGNS, LEAVE IT SIMPLE. THERE IS NO NEED FOR AN IN-DEPTH ANALYSIS.
CME_MINI:ES1!Long
by GeneticHustle
S&P 500 - Elliott Wave Analysis - CorrectionHi All, What a strong close today for SPY. It certainly took Bears on surprise, the bigger surprise was Nasdaq strong pull back to green as there's a lot of FUD around inflation, which is true but FAANG stocks are too cheap to be ignore for long. Again, correction can be very tricky, I'll not assume or jump into any conclusion, we're still sitting in correction, and there're various ways Eliott's Correction can take place in ABC pattern, so place your bets accordingly. Good luck.
SP:SPX
by ActorBay
3
$NNDM Target PTs 11.50-16Nano Dimension Ltd., together with its subsidiaries, provides additive electronics in Israel and internationally. Its flagship product is the proprietary DragonFly lights-out digital manufacturing (LDM) system, a precision system that produces professional multilayer circuit-boards, radio frequency antennas, sensors, conductive geometries, and molded connected devices for prototyping through custom additive manufacturing. The company also provides nanotechnology based conductive and dielectric inks; and DragonFly and Switch software to manage the design file and printing process. It markets and sells products and services to companies that develop products with electronic components, including companies in the defense, automotive, consumer electronics, semiconductor, aerospace, and medical industries, as well as research institutes. The company was founded in 2012 and is headquartered in Ness Ziona, Israel.
NASDAQ:NNDMLong
by UnknownUnicorn19246015
$XELA entry PT 1.70-1.85 PT 7 and higherExela Technologies, Inc. provides transaction processing solutions, enterprise information management, document management, and digital business process services worldwide. The company operates through three segments: Information & Transaction Processing Solutions (ITPS), Healthcare Solutions (HS), and Legal & Loss Prevention Services (LLPS). The ITPS segment provides lending solutions for mortgages and auto loans; banking solutions for clearing, anti-money laundering, sanctions, and interbank cross-border settlement; property and casualty insurance solutions for origination, enrollments, claims processing, and benefits administration communications; and public sector solutions for income tax processing, benefits administration, and records management. It also offers solutions for payment processing and reconciliation, integrated receivable and payables management, document logistics and location services, records management, and electronic storage of data/documents; and software, hardware, professional services, and maintenance related to information and transaction processing automation. The HS segment provides revenue cycle solutions, integrated accounts payable and accounts receivable, and information management for healthcare payer and provider markets. The LLPS segment processes legal claims for class action and mass action settlement administrations, involving project management support, notification, and outreach to claimants; and collects, analyzes, and distributes settlement funds. It also offers data and analytical services in the area of litigation consulting, economic and statistical analysis, expert witness services, and revenue recovery services for delinquent accounts receivable. The company is headquartered in Irving, Texas.
XLong
by BADQOMOCAWGOWLD
$BRPA entry PTs 31-33 PT 62-70 and higher...SPACsClinically proven COVID therapeutic Clinically proven COVID therapeutic BRIAN ALTERIO Bellefonte In my research, I have found that the Zyesami/Aviptadil COVID-19 therpeautic has proven successful in meeting primary and secondary enpoints, preventing people who are critically ill from the virus from dying. The success is based on Phase II and Phase III trials. Therapeutic trials were conducted by NeuroRx, a private company based here in Pennsylvania. The terapeutic’s owner, Relief Therapeutics (ticker: RLFTF) is a Geneva, Switzerland-based company. The FDA has had access to the complete trial data set for nearly a month now, and regardless of Zyesami/Aviptadil’s proven efficacy, the FDA is seemingly dragging its feet, while thousands of people continue to NEEDLESSLY die EVERY day, who could potentially be saved by this therapeutic. Zyesami/Aviptadil achieved both statistical and clinical significance in meeting ALL of its primary and secondary endpoints. The p-values demonstrating statistical significance were extremely low, which means the likelihood of these results occurring by random chance are also extremely low. Additionally, people who received Zyesami/Aviptadil went home from the hospital an average of 11 to 13 days sooner than people who received the placebo, which in this case was SOC (“standard of care”) that included the treatment Remdesivir. We have seen Big Pharma’s vaccines get pushed through the EUA process with relative ease and “lightning speed,” for the FDA…we’re talking just a couple of weeks for some of them, and some of which, I might add, are now halted due to blood clotting concerns…while the proven safe and successful therapeutic Zyesami/Aviptadil waits indefinitely on the sidelines for its EUA to begin saving people here in the States, and elsewhere in the world. (You can form your own opinions as to why that’s happening.) The trial’s results are readily available for review online…all you have to do is search for it. This story is too important to turn a blind eye to. Please, get this story covered and reported.
BLong
by BADQOMOCAWGOWLD
$VLDRVelodyne Lidar, Inc. provides real-time three-dimensional vision for autonomous systems worldwide. It offers a broad lineup of surround-view lidar to support numerous end applications, including autonomous vehicles, drones, security, and mapping; and solid state lidar technology that combine the high reliability and long lifetime of traditional micro electro-mechanical systems solutions. The company also provides Vella software solution to any vehicle that utilizes a Velarray lidar. Its lidar-based smart vision solutions are also used in non-automotive applications, such as autonomous mobile robots, unmanned aerial vehicles, last-mile delivery, precision agriculture, advanced security systems, and smart city initiatives. Velodyne Lidar, Inc. was founded in 1983 and is headquartered in San Jose, California.
VLong
by UnknownUnicorn19246015
1
BUY $KGC - NRPicks Nov 29Kinross Gold es un productor senior de oro con sede en Canadá, que produce aproximadamente 2,5 millones de onzas equivalentes de oro en 2019. La compañía tenía 24,3 millones de onzas de reservas de oro probadas y probables y 55,7 millones de onzas de reservas de plata a finales de 2019. Opera minas y centra su exploración de campos verdes y brownfield en las Américas, el oeste de Africa y Rusia y está ubicada dentro de las 19 compañías mineras de oro más importantes del mundo. Lo más obvio es pensar que a medida que el optimismo sobre el avance de las vacunas ha mejorado en los últimos meses, la incertidumbre - que era uno de los factores de compra del metal - se ha ido reduciendo. Otro de los patrones en el último año ha sido la correlación indirecta entre la debilidad del dólar y la fortaleza del oro, la cual no ha sido vista en los últimos meses, porque ambos activos han venido retrocediendo (Este es un dato para observar). Pero aún así el metal ha respetado patrones técnicos desde el 2019 y beneficiado de un gran impulso por la pandemia. En estos momentos el oro se ubica por debajo de su SMA 200 y probablemente sea lo que la mayoría de inversores esté viendo como oportunidad. Si el patrón se cumple deberíamos esperar la evolución de un nuevo objetivo para el oro, primero intentando recuperar los $2000. Si esto se diera, las perspectivas para KGC mejorarían y sería beneficiado en las siguientes semanas logrando alcanzar los $8.50 por acción. Recordemos que estamos en el momento más especulativo del mercado, muchas distorsiones generadas a raíz de la liquidez, los inversores han venido mostrando patrones algo predecibles y podrían confluir en estos niveles.
NYSE:KGCLong
by NewroadTrader